APA (7th ed.) Citation

Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., . . . Fontenay, M. (2009). TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114(15), 3285. https://doi.org/10.1182/blood-2009-04-215814

Chicago Style (17th ed.) Citation

Kosmider, Olivier, et al. "TET2 Mutation Is an Independent Favorable Prognostic Factor in Myelodysplastic Syndromes (MDSs)." Blood 114, no. 15 (2009): 3285. https://doi.org/10.1182/blood-2009-04-215814.

MLA (9th ed.) Citation

Kosmider, Olivier, et al. "TET2 Mutation Is an Independent Favorable Prognostic Factor in Myelodysplastic Syndromes (MDSs)." Blood, vol. 114, no. 15, 2009, p. 3285, https://doi.org/10.1182/blood-2009-04-215814.